Potentially, checkpoint inhibitors targeting PD-1, PD-L1 and CTLA-4 could counteract immunosuppressive cells populations that dominate the tumor microenvironment in esophageal squamous cell carcinoma. This evidence concerns the gene CD274 and neoplasm.